Ultragenyx Pharmaceutical RARE reported its Q1 earnings results on Thursday, May 4, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Ultragenyx Pharmaceutical missed estimated earnings by 17.68%, reporting an EPS of $-2.33 versus an estimate of $-1.98.
Revenue was up $20.56 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.02 which was followed by a 10.03% increase in the share price the next day.
Here's a look at Ultragenyx Pharmaceutical's past performance:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -2.14 | -1.81 | -1.75 | -1.76 |
EPS Actual | -2.16 | -2.43 | -2.26 | -2.19 |
Revenue Estimate | 105.12M | 96.20M | 87.51M | 83.65M |
Revenue Actual | 103.35M | 90.70M | 89.34M | 79.94M |
To track all earnings releases for Ultragenyx Pharmaceutical visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.